Lamellar body mimetics with potential therapeutic applications.
Lamellar Biomedical Ltd is pleased to provide you with news and information on the Company and its areas of interest:
Press release: 7 January 2013
Lamellar Biomedical is pleased to announce that it has raised £3.3 million in equity financing from existing and new
shareholders including Barwell, Scottish Enterprise and TRI Cap angel investors. Funds managed by Invesco Perpetual
form the core of the new shareholding.
Press release: 16 June 2011
Glasgow biopharmaceutical firm, Lamellar Biomedical Ltd, launched four years ago to develop a new class of therapies for the prevention, treatment and control of severe respiratory disease, today announced that their lead clinical candidate LMS-611 for the treatment of patients with cystic fibrosis has ... more>>
Press release: 18-21 May 2009
Press release: 12-14 October 2008
Press release: 18 September 18 2008
Press release: 17 September 2007
A Bellshill-based firm, which is planning to pioneer a new treatment for cystic fibrosis and other respiratory diseases, has received a funding boost of nearly £1m from a consortium of investors, instigated by... more>>
For further information please contact Lamellar Biomedical
Tel: +44 (0) 1698 748832 Fax: +44 (0) 1698 849500 Email: firstname.lastname@example.org